MyoGene Bio
Company Type: Therapeutic development
Main focus: Developing novel therapeutics for muscle diseases
Company stage: Pre-clinical
Diseases: Duchenne muscular dystrophy and other muscular diseases
Genome-editing tool: CRISPR-Cas9
Funding stage: Unknown.
Location: San Diego, California, USA
Website: http://www.myogenebio.com/x4555.html
Pipeline:
Partners:
MyoGene Bio is a biotechnology company specialising in the development of genetic therapies for muscle diseases such as Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy. Their main focus, MyoDys45-55, surrounds the development of a novel CRISPR-Cas9 gene-editing platform to treat DMD. MyoDys45-55 is currently at pre-clinical stage and has demonstrated efficient restoration of the dystrophin protein in mice and human stem cells.